Crossmark

Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens

Crossref DOI link: https://doi.org/10.1007/s40272-018-0295-z

Published Online: 2018-05-08

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Marsot, Amélie https://orcid.org/0000-0002-9303-8862
Gallais, F.

Galambrun, C.

Coze, C.

Blin, O.

Andre, N.

Guilhaumou, R.
License Information

Text and Data Mining valid from 2018-05-08
More Information

Article History

First Online: 8 May 2018

Compliance with Ethical Standards

:

: Ethical approval was granted by the local ethics committee Aix Marseille Université (no. 2016-28-09-04).

: AM, FG, CG, CC, OB, NA, RG have no conflicts of interest.

: No sources of funding were used to support this work.

Document is current

Any future updates will be listed below